Orion Oyj/€ORNBV
1D1W1MYTD1Y5YMAX
Capital at risk
About Orion Oyj
Orion Oyj is a Finnish pharmaceutical and diagnostics company engaged primarily in the research, development, manufacturing, and marketing of pharmaceuticals and active pharmaceutical ingredients. It operates through two main segments: the Pharmaceuticals segment, which includes proprietary drugs, specialty products, and animal health, and the Diagnostics segment, which comprises the Orion Diagnostica company focused on diagnostic tests. Founded in 1917, Orion is headquartered in Espoo, Finland, and operates globally with a significant presence in the Nordic countries and significant partnerships worldwide. Orion's strategic focus includes a strong emphasis on its proprietary drug portfolio, particularly in the central nervous system and oncology sectors, which constitutes a crucial component of its competitive strengths.
- Ticker
- €ORNBV
- Sector
- Health
- Primary listing
- XHEL
- Employees
- 4,000
- Headquarters
- Espo, Finland
- Website
- www.orionpharma.com
Orion Oyj Metrics
BasicAdvanced
€11B
19.15
€4.17
0.29
€1.72
2.15%
Price and volume
Market cap
€11B
Beta
0.29
52-week high
€82.50
52-week low
€57.30
Average daily volume
143K
Dividend rate
€1.72
Financial strength
Current ratio
2.639
Quick ratio
1.483
Long term debt to equity
0.081
Total debt to equity
0.105
Dividend payout ratio (TTM)
41.34%
Interest coverage (TTM)
91.44%
Profitability
EBITDA (TTM)
794
Gross margin (TTM)
65.93%
Net profit margin (TTM)
28.53%
Operating margin (TTM)
35.99%
Effective tax rate (TTM)
20.31%
Revenue per employee (TTM)
€510,000
Management effectiveness
Return on assets (TTM)
26.31%
Return on equity (TTM)
53.65%
Valuation
Price to earnings (TTM)
19.155
Price to revenue (TTM)
5.465
Price to book
8.84
Price to tangible book (TTM)
10.39
Price to free cash flow (TTM)
29.571
Free cash flow yield (TTM)
3.38%
Free cash flow per share (TTM)
2.702
Dividend yield (TTM)
2.15%
Growth
Revenue change (TTM)
22.73%
Earnings per share change (TTM)
55.11%
3-year revenue growth (CAGR)
14.98%
10-year revenue growth (CAGR)
7.11%
3-year earnings per share growth (CAGR)
24.13%
10-year earnings per share growth (CAGR)
10.64%
3-year dividend per share growth (CAGR)
4.00%
10-year dividend per share growth (CAGR)
3.31%
Bulls say / Bears say
Orion reported Q2 2026 net sales of €521.6 million, up 25.2% year-on-year, reflecting robust demand across its proprietary and specialty pharmaceuticals. (Reuters)
Operating profit surged by 68.8% to €176.6 million in Q2, propelled by strong Nubeqa® royalty growth, demonstrating the high-margin leverage of its specialty portfolio. (Reuters)
Management raised the lower bound of its 2026 net sales guidance to €2.0–2.1 billion from €1.95–2.1 billion, signalling confidence in sustaining revenue momentum into year-end. (Reuters)
In Q1 2026, Orion’s sales of €417.7 million missed consensus of €426.1 million, and operating profit of €114.8 million fell short of the €116.7 million estimate, underscoring exposure to rising R&D and marketing expenses as well as cost‐inflation risk. (Reuters)
The H1 2026 performance was significantly boosted by a one-off €180 million Nubeqa® milestone payment recognised in Q4 2025, which may not recur and could lead to a normalization of profitability in later quarters. (Orion H1 Report)
In March 2026, BlackRock’s beneficial ownership in Orion fell below 5%, potentially signalling waning institutional support and increased share‐price volatility. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2026.
Upcoming events
Funds containing Orion Oyj
AllEURGBPUSD
Fund name | Fund size | €ORNBV weighting |
|---|---|---|
SPDR S&P Euro Dividend Aristocrats€EUDV | €1.8B | 1.66% |
SPDR S&P Euro Dividend Aristocrats£EUDV | £1.6B | 1.66% |
iShares Healthcare Innovation$HEAL | $1.4B | 1.13% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.13% |
iShares Healthcare Innovation£DRDR | £1B | 1.13% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.